Small molecules remain a dominant force in the pharmaceutical industry due to their high bioavailability, well-established production processes, and regulatory clarity. In this landscape, small molecule CDMO plays a critical role in accelerating innovation, managing complexity, and ensuring scalable production.
As a reliable small molecule CDMO partner, ChemExpress supports pharmaceutical and biotech clients’ projects across the full lifecycle of drug development—from early discovery and process development to commercialization. With a strong commitment to innovation and regulatory compliance, we deliver high-quality solutions including RSM, intermediate, API, HPAPI, and drug products. Our integrated platform helps accelerate the journey of small molecule from R&D to commercialization.
From R&D to commercialization, we integrate CRO & CDMO capabilities across small molecules—delivering end-to-end services in RSM, intermediate, API, HPAPI and drug products.
We specialize in complex chemistry—chiral molecules, HPAPI, heterocycles, ADC linkers, and etc.— with enabling technologies including flow chemistry, High Throughput Experimentation, biocatalysis, and Solubility-Enhancing Technologies.
With Multiple GMP-compliant sites, we ensure regulatory excellence. Our tailored CDMO strategies help reduce costs, minimize tech transfer, and accelerate the path to market.
ChemExpress combines deep chemistry expertise with global regulatory compliance experience, supporting the small molecule CDMO landscape to accelerate development and minimize risk—empowering our clients to seize market opportunities faster.
Juancheng R&D Center
Zaozhuang Fermentation Production Base
Zaozhuang Fermentation Production Base
Zaozhuang Fermentation Production Base
We specialize in complex synthesis routes and accelerate drug discovery through flexible collaboration models and cost-effective R&D strategies.
We provide scalable and cost-effective processes, ensuring a smooth transition to GMP production and supporting technology transfer.
We provide integrated Drug Substance services—from early-stage process optimization to GMP production and regulatory support.
We provide comprehensive manufacturing capabilities for multiple dosage forms, including oral solids (tablets, capsules, granules, powders) and semi-solids (creams, ointments, gels).
Well experienced with the regulatory management and requirements for pharmaceutical products in the USA, China, Japan and EU. We successfully assisted clients in a total of 150+ US-China dual IND filing cases.
We provide comprehensive method development, validation, stability studies, ICH-compliant testing, and have fully equipped analytical instruments and GMP labs to ensure the quality of drug substances and drug products.
An API is the chemically active substance in a medication that produces the intended therapeutic effect. Drug products (formulations) combine APIs with excipients (such as starch, lactose) in specific ratios to create the final dosage forms for patient use, including tablets, capsules, and injections. Simply put, APIs are the "active components" while drug products are the "finished medicines."
We possess deep expertise in complex small molecule synthesis, specializing in challenging chemical structures including chiral molecules, highly potent APIs (HPAPIs), heterocyclic compounds, and ADC payloads. Our advanced technology platforms encompass continuous flow chemistry, high-throughput experimentation (HTE), biocatalysis, and bioavailability enhancement technologies. We maintain comprehensive analytical capabilities ensuring end-to-end quality control from starting materials to final products.
We have established a comprehensive cGMP quality management system with manufacturing facilities compliant with international regulatory standards including FDA, EMA, and NMPA requirements. We rigorously follow ICH guidelines and have implemented complete quality risk management and deviation handling procedures. Our professional stability study capabilities support clients throughout the entire regulatory journey from IND to NDA, facilitating successful regulatory approvals across major global markets.
Address:F4, Building 7, DIYA Innovation Park, No. 2566, Century Avenue Road, High tech Zone, Jinan city, Shandong Province, ChinaE-mail：sales@h2opharm.com
Phone：+86 15098843573
